用一种突变特异性小分子激活p53Y220C
Xijun Zhu1,2, Woong Sub Byun3,2, Dominika Ewa Pieńkowska4
1Department of Chemistry, Stanford University, Stanford, CA, USA.
bioRxiv : the preprint server for biology
|November 18, 2024
概括
研究人员开发了TRanscriptional Activator of p53 (TRAP-1),这是一种新型化合物,可以重新激活突变的瘤抑制蛋白p53. TRAP-1激活突变p53,恢复其瘤抑制功能并抑制癌细胞生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- TP53基因是人类癌症中最常发生突变的基因.
- 突变的p53蛋白经常失去其瘤抑制功能,并且很难在治疗上准.
- 恢复p53功能是癌症治疗的一个关键目标.
研究的目的:
- 发现和描述一种能够重新激活突变p53.3的小分子.
- 为了研究这种新型化合物的作用机制.
- 在癌症模型中评估重新激活突变p53的治疗潜力.
主要方法:
- 发现了一种近距离的小分子化学诱导剂,称为p53的转录激活剂 (TRAP-1).
- 描述TRAP-1与突变p53和BRD4.4形成三元复合物的能力.
- 用TRAP-1治疗表达p53Y220C的胰腺癌细胞系.
- 对p53目标基因转录 (例如,p21) 和细胞生长抑制的分析.
- 使用缺乏三元复合形成能力的对照化合物.
主要成果:
- TRAP-1成功地与突变p53和BRD4接触,形成了一个三元复合体.
- 这种复杂的形成有力地激活突变p53并诱导p53基因的强有力的转录.
- 在p53Y220C表达细胞中,TRAP-1治疗导致了p21和其他向基因的快速上调.
- TRAP-1 抑制了这些特定癌症细胞系的生长.
- 没有三元复合形成能力的对照化合物没有产生类似的结果.
结论:
- 化学诱导的接近是一种可行的策略,用于重新激活像p53.3这样的突变瘤抑制蛋白.
- TRAP-1 证明了这种方法在恢复癌症中失去的瘤抑制功能方面的潜力.
- 这一发现为开发针对具有TP53突变的癌症的疗法开辟了新的途径.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
DNA Damage can Stall the Cell Cycle
9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Negative Regulator Molecules
35.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Conservative Site-specific Recombination and Phase Variation
5.9K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
5.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


